Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of alkyl phenylketones and ureas. It contains a brominated pyridine ring and a fluorinated phenol moiety linked via a cyclopropane group to a urea core. The compound is listed as an experimental molecule with no approved medical indications or known clinical development status. Its mechanism of action, biological targets, therapeutic area, and developer are not described in public databases. No evidence suggests it has reached clinical trials or regulatory approval stages[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-(5-bromo-pyridin-2-yl)-3-[2-(6-fluoro-2-hydroxy-3-propionyl-phenyl)-cyclopropyl]-urea.